Lijun Shi1, Jingwen Liao2, Bailin Liu2, Fanxing Zeng2, Lubo Zhang3. 1. Department of Exercise Physiology, Beijing Sport University, Beijing 100084, China. Electronic address: l_j_shi72@163.com. 2. Department of Exercise Physiology, Beijing Sport University, Beijing 100084, China. 3. Center for Perinatal Biology, Division of Pharmacology, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Abstract
Hypertension is the major risk factor for the development of stroke, coronary artery disease, heart failure and renal disease. The underlying cellular and molecular mechanisms of hypertension are complex and remain largely elusive. MicroRNAs (miRNAs) are short, noncoding RNA fragments of 22-26 nucleotides and regulate protein expression post-transcriptionally by targeting the 3'-untranslated region of mRNA. A growing body of recent research indicates that miRNAs are important in the pathogenesis of arterial hypertension. Herein, we summarize the current knowledge regarding the mechanisms of miRNAs in cardiovascular remodeling, focusing specifically on hypertension. We also review recent progress of the miRNA-based therapeutics including pharmacological and nonpharmacological therapies (such as exercise training) and their potential applications in the management of hypertension.
Hypertension is the major risk factor for the development of pan class="Disease">stroke, coronary artery disease, heart failure and renal disease. The underlying cellular and molecular mechanisms of hypertension are complex and remain largely elusive. MicroRNAs (miRNAs) are short, noncoding RNA fragments of 22-26 nucleotides and regulate protein expression post-transcriptionally by targeting the 3'-untranslated region of mRNA. A growing body of recent research indicates that miRNAs are important in the pathogenesis of arterial hypertension. Herein, we summarize the current knowledge regarding the mechanisms of miRNAs in cardiovascular remodeling, focusing specifically on hypertension. We also review recent progress of the miRNA-based therapeutics including pharmacological and nonpharmacological therapies (such as exercise training) and their potential applications in the management of hypertension.
Authors: Deug-Chan Lee; Roberto Romero; Jung-Sun Kim; Adi L Tarca; Daniel Montenegro; Beth L Pineles; Ernest Kim; JoonHo Lee; Sun Young Kim; Sorin Draghici; Pooja Mittal; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Sonia S Hassan; Chong Jai Kim Journal: Am J Pathol Date: 2011-08 Impact factor: 4.307
Authors: Paola Caruso; Yvonne Dempsie; Hannah C Stevens; Robert A McDonald; Lu Long; Ruifang Lu; Kevin White; Kirsty M Mair; John D McClure; Mark Southwood; Paul Upton; Mei Xin; Eva van Rooij; Eric N Olson; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker Journal: Circ Res Date: 2012-06-19 Impact factor: 17.367
Authors: Lijuan Guo; Yuanhua Yang; Jie Liu; Lei Wang; Jifeng Li; Ying Wang; Yan Liu; Song Gu; Huili Gan; Jun Cai; Jason X-J Yuan; Jun Wang; Chen Wang Journal: PLoS One Date: 2014-06-30 Impact factor: 3.240
Authors: Ryan S Friese; Angelina E Altshuler; Kuixing Zhang; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Martin L Jirout; Rany M Salem; Jiaur R Gayen; Nitish R Mahapatra; Nilima Biswas; Mo Cale; Sucheta M Vaingankar; Hyung-Suk Kim; Maïté Courel; Laurent Taupenot; Michael G Ziegler; Nicholas J Schork; Michal Pravenec; Sushil K Mahata; Geert W Schmid-Schönbein; Daniel T O'Connor Journal: Hum Mol Genet Date: 2013-05-13 Impact factor: 6.150
Authors: Sébastien Bonnet; Olivier Boucherat; Roxane Paulin; Danchen Wu; Charles C T Hindmarch; Stephen L Archer; Rui Song; Joseph B Moore; Steeve Provencher; Lubo Zhang; Shizuka Uchida Journal: Am J Physiol Cell Physiol Date: 2019-09-04 Impact factor: 4.249
Authors: Lilach O Lerman; Theodore W Kurtz; Rhian M Touyz; David H Ellison; Alejandro R Chade; Steven D Crowley; David L Mattson; John J Mullins; Jeffrey Osborn; Alfonso Eirin; Jane F Reckelhoff; Costantino Iadecola; Thomas M Coffman Journal: Hypertension Date: 2019-06 Impact factor: 10.190